Provepharm continues its international expansion by signing three new distribution agreements in Europe

06-Jul-2012 - Provepharm announced that it has extended its international distribution network by signing new agreements covering eight additional European countries.Provepharm has recently concluded one licensing and distribution agreement with NordMedica for the distribution of its product in the five ...

Provepharm signs license agreement with Daiichi Sankyo to provide methylthioninium chloride Proveblue solution for injection to Japan

Daiichi Sankyo will resolve the unmet need for an approved methylthioninium chloride injectable drug in Japan

01-Dec-2011 - Provepharm announced that it has entered into an exclusive licensing agreement with Daiichi Sankyo to make Provepharm’s injectable medicinal product, Methylthioninium chloride Proveblue, available in Japan. The Proveblue medicinal product is used for the treatment of methaemoglobinaemia induced ...

Provepharm obtains European marketing authorization for its Methylthioninium Chloride Proveblue

26-May-2011 - Provepharm announced that it has just received official marketing authorization for its Methylthioninium Chloride Proveblue from the European Medicines Agency. This authorization means that clinicians will be able to treat European patients for the first time with this injectable drug based on ...

Provepharm receives favorable EMA Review of its methylthioninium chloride Proveblue

15-Mar-2011 - Provepharm, a start-up specialized in the development of pharmaceutical applications, announced that, following a one-year centralized review procedure, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CMPH) issued a favorable assessment of its methylthioninium ...